EMA Authorised: Sitagliptin / Metformin hydrochloride Sun (sitagliptin fumarate;metformin hydrochloride) — Sun Pharmaceutical Industries Europe B.V.

View source ↗

Summary

EMA authorised Sun Pharmaceutical's fixed-dose combination of sitagliptin fumarate and metformin hydrochloride for type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• METFORMIN HYDROCHLORIDE (Metformin hydrochloride)
• Sitagliptin fumarate (sitagliptin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Sun Pharmaceutical Industries Europe B.V.. Decision date: 11/04/2025